|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mst1/2 inhibition of Yap1 is an important pathway for tumor suppression in liver relevant to human HCC.
|
19878874 |
2009 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The present study aims to elucidate the transcriptional regulation of YAP targeted by microRNA (miRNA). miR-375 is a putative target and was found significantly down-regulated in the tumor versus adjacent non-tumor tissues of HCC patients (n=48).
|
20226166 |
2010 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have recently defined the tumorigenic potential and clinical significance of the YAP1 oncogene in human hepatocellular carcinoma (HCC).
|
21076472 |
2011 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Amplification of the YAP gene and overexpression of YAP in HCC have previously been reported to contribute to hepatocyte malignant transformation and tumor progression.
|
23232767 |
2013 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Increased menin and Yap1 expression in human hepatocellular carcinoma specimens was associated with poor prognosis.
|
24101467 |
2013 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We observed nuclear localization of β-catenin and Yap1 in 79% of hepatoblastoma samples but not in most hepatocellular carcinoma or intrahepatic cholangiocarcinoma samples.
|
24837480 |
2014 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.
|
24884509 |
2014 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bioinformatics analysis revealed that YAP mRNA might be one of the targets of miR-506, and miR-506 in HCC tissues was found to be negatively correlated with YAP (r=-0.605).
|
25087998 |
2014 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The inactivation of the Hippo pathway lead to TAZ (PDZ-binding motif)/YAP (yes-associated protein) overexpression, and is associated with worse prognostic outcomes in various cancers including hepatocellular carcinoma (HCC).
|
26125451 |
2015 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The recently discovered positive feedback loop between activated YAP1 and increased EGFR/KRAS signalling found in oesophageal, ovarian and hepatocellular cancer has been related to the CRC progression and resistance to EGFR inhibitors during CRC therapy.
|
26160682 |
2015 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that the administration of SN28 together with the suppression of YAP using statins is a promising strategy for enhancing the treatment response in HCC patients, particularly in advanced stage HCC cases presenting hypoxic resistance.
|
26771844 |
2016 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
miR-199a-3p targets YAP1, downregulates Jagged1 and suppresses the Notch signaling to inhibit HCC cell proliferation and promote apoptosis.
|
27832779 |
2016 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression and activation of YAP-1 in HCC T cells can induce immunosuppression by promoting Treg differentiation via transcriptional enhancement of TGFBR2.
|
28472799 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
For HCCs, a trend of poor progression-free survival for YAP1(+) HCCs was observed (39 ± 18 vs. 81 ± 5 months, mean ± SD, log rank p-value 0.205) CONCLUSIONS: YAP1 activation was more commonly found in CCAs than in pure HCCs.
|
28645247 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, plasmacytoma variant translocation 1 served as an endogenous sponge for miR-186-5p to reduce its inhibiting effect on yes-associated protein 1 and thus promoted the tumorigenesis of hepatocellular carcinoma.
|
28656879 |
2017 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Pearson's correlation coefficient analysis indicated WWC2 expression correlated inversely with nuclear YAP protein expression in HCC.
|
28815883 |
2017 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, we showed that MCP1 is a direct transcription target of YAP in hepatocytes and identified a strong gene expression correlation between YAP targets and MCP-1 in human HCCs.
|
28866620 |
2018 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we confirmed yes-associated protein 1 (YAP1) was up-regulated in HCC cells and tissues, and overexpression of YAP1 promoted HCC cell proliferation and migration.
|
29187885 |
2017 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Activation of YAP/TEAD signaling is very common in the progression of HCC (Hepatocellular carcinoma).
|
29228669 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Notably, this study confirmed that miR-195, YAP and their combination were valuable predictors for the prognosis of HCC patients.
|
29245938 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, we found that FR5 effectively inhibits proliferation and induces apoptosis of HCC cells through coordinated inhibition of YAP in the Hippo pathway and AKT in the PI3K-PTEN-mTOR pathway, and suggest FR5 as a potential therapy for HCC.
|
29299170 |
2017 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A high level of YAP/ TAZ expression was associated with a high level of IRS2 expression in human hepatocellular carcinoma (HCC).
|
29400692 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, the EGFR-PI3K-PDK1 pathway could activate the YAP signaling, and the activated EGFR signaling could promote the HCC cell growth in a YAP-independent manner.
|
29449645 |
2018 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this paper, we showed that COX-2 overexpression in HCC cell lines resulted in increased levels of YAP mRNA, protein, and its target genes.
|
29505957 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
AXIN1-mutated HCCs occur independently of the Wnt/β-catenin pathway and involve Notch and YAP pathways.
|
29525529 |
2018 |